HOME >> BIOLOGY >> NEWS
Interim long-term follow-up data show AMG 531 increases platelets in patients with ITP

dministration of AMG 531 in both pre- and post-splenectomy ITP patients. Eligible patients had completed a previous AMG 531 study in ITP and had a baseline platelet count of less than 50,000 platelets per microliter, with no recent significant change in medical history. The AMG 531 starting dose was 1 g/kg by subcutaneous injection with dose adjustment to a maximum of 15 g/kg. Patients were administered AMG 531 by injection once weekly unless their platelet count exceeded 400,000 platelets per microliter. Once patients reached a stable dose and schedule, physician office visits were reduced from weekly to once per month. Concurrent corticosteroid treatment could be tapered when patients' platelet counts reached 50,000 platelets per microliter. The study is available for patients completing the two ongoing Phase 3 AMG 531 studies in ITP.


'"/>

Contact: Trish Hawkins
805-447-4587
Porter Novelli
12-Dec-2005


Page: 1 2 3

Related biology news :

1. Interim analysis of anti-cancer vaccine, BiovaxID, to be conducted
2. Interim Aranesp data suggest major response in anemic patients with MDS
3. Interim data suggest major response with Aranesp(R) in anemic patients with MDS
4. Macho men are seen as bad choice for long-term love
5. DOE Joint Genome Institute secures long-term lease on production genomics facility
6. Cancer drug enhances long-term memory
7. UT Southwestern joins national clinical trial to uncover long-term effects of West Nile virus
8. New study sheds light on long-term effects of logging after wildfire
9. Common fungicide causes long-term changes in mating behavior
10. Prenatal exposure to glucocorticoids has long-term deleterious effects on newborns
11. Why is long-term therapy required to cure tuberculosis?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
Cached News: